Syncopation Life Sciences is an adoptive cell therapy company recently launched by founders from Stanford University in partnership with Samsara BioCapital. We are developing novel, CAR T-based technologies and programs to address important drivers of resistance to first-generation cell therapies. The company is based in the San Francisco Bay Area, where we are building a team of talented scientists and drug developers to bring a new generation of cell therapies to the clinic.
Location: United States, California, Palo Alto
Employees: 11-50
Total raised: $200M
Investors 2
| Date | Name | Website |
| 05.01.2022 | MBC BioLab... | mbcbiolabs... |
| 10.11.2022 | Red Tree V... | redtreevc.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.03.2023 | Series A | $200M | - |
Mentions in press and media 4
| Date | Title | Description |
| 01.03.2023 | CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies | - |
| 01.03.2023 | Cargo Therapeutics Raises $200M in Upsized Series A Financing | Cargo Therapeutics, Inc., a San Mateo, CA-based biotechnology company advancing a next generation of CAR T-cell therapies for cancer, closed a $200m upsized Series A financing. The round was co-led by Third Rock Ventures, RTW Investments, L... |
| 01.03.2023 | CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies | - |
| 01.03.2023 | CARGO Therapeutics Lands $200M Series A | SAN MATEO, CA, CARGO Therapeutics, a biotechnology company, announced the close of a $200 million oversubscribed and upsized Series A financing. >> Click here for more funding data on CARGO Therapeutics >> To export CARGO Th... |